Benign Prostatic Hyperplasia Prostate Treatment Market 2034

Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market Outlook for 2024 to 2034

The benign prostatic hyperplasia (BPH) prostate treatment market is anticipated to be worth US$ 33,031.10 million in 2024. The market is expected to grow at a steady rate over the period from 2024 to 2034, with a CAGR of 3.6%. By the end of the forecast period, the market value is predicted to hit US$ 47,045.80 million.

Attributes	Details
Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market Value for 2024	US$ 33,031.10 million
Projected Market Value for 2034	US$ 47,045.80 million
Value-based CAGR of Market for 2024 to 2034	3.6%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market Insights

Rising number of people suffering from benign prostatic hyperplasia and prostate problems in general is informing the growth in demand for the treatment.
With growing preference towards minimally invasive surgeries, the demand for treatment procedures like transurethral needle ablation (TUNA) and prostatic urethral lift (PUL) is increasing.
Increasing reputation of prostate artery embolization (PAE), due to its positive results, is helping the market’s growth.
Innovations such as Optilume drug-coated balloon in benign prostatic hyperplasia (BPH) prostate treatment are aiding in the development of the market.
Rise in the geriatric population is leading to an increase in patients with benign prostatic hyperplasia, expanding the scope of the market.

Trends in BPH Prostate Treatment Market

Development of irregular eating habits due to the busy lifestyles of the youth is leading to an increase in BPH problems, necessitating the use of benign prostatic hyperplasia (BPH) prostate treatment.
Increasing number of patients are opting for homeopathy and natural remedies for BPH and thus the market has multiple avenues for growth.
Initiatives taken by governments to advance the healthcare system in their countries are creating a conducive environment for the market’s progress.
Alpha blockers remain popular as a form of treatment for BPH and the continuing demand for the drugs is benefitting the market.
Risk of side effects such as urinary tract infection treatment and kidney damage limit the prospects of the market.
High cost of BPH prostate treatment, especially those using devices, is set to hinder the growth of the market.
Scientific skepticism over BPH home remedies and homeopathy solutions is set to restrict the growth of the market through those avenues.

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Category-wise Outlook

Drugs continue to be the preferred treatment type for BPH. Institutional sales top the distribution channel segment.

Easy Administering Capabilities and Development of New Products Make Sure Drugs Remain the Predominant Treatment Type

For 2024, drugs are expected to account for 65.2% of the market share by treatment type. Some of the key drivers for the increasing use of drugs in BPH treatment are:

Easy administration of drugs makes them popular as forms of treatment in the wider healthcare sector and that popularity is reflected in the benign prostatic hyperplasia (BPH) prostate treatment market.
Development of drugs like tadalafil for BPH treatment, previously used exclusively to treat erectile dysfunction, is helping drugs to infiltrate further in the treatment of patients.

Attributes	Details
Top Treatment Type	Drugs
Market Share (2024)	65.2%

Increase in Research Related to Prostate-related Problems is Seeing Institutional Sales Grow

Institutional sales are anticipated to account for 64.7% of the market share in 2024. Some of the key drivers for the progress of institutional sales include:

Research institutes are receiving funding from both the private and public sectors in an increasing manner. Thus, their buying capacity is increasing, and institutional sales of BPH treatment are growing.
Proliferation of specialty clinics trading in minimally invasive surgeries is benefitting the development of institutional sales of BPH treatment.

Attributes	Details
Top Distribution Channel	Institutional Sales
Market Share (2024)	64.7%

Country-wise Analysis

The increasing geriatric population is contributing to the market’s acceleration in North America. The presence of a wide variety of treatments is also propelling the benign prostatic hyperplasia (BPH) prostate treatment industry in North America.

Advancement of research institutions is lending a helping hand to the progress of the market in the region. The focus on the technological development of healthcare companies in the region is making sure BPH treatment keeps up with the times in Europe.

Countries	CAGR
United States	4.0%
Canada	3.1%
United Kingdom	3.7%
France	3.3%
Italy	3.5%

Approval of New Treatment Methods Keeping Market Demand Flowing in the United States

The market is set to register a CAGR of 4.0% in the United States for the forecast period. The key drivers for growth are:

Innovative treatment procedures for benign prostatic hyperplasia, such as the Optilume BPH catheter system, getting approvals at a faster rate is seeing the market develop positively in the United States.
Transurethral resection of the prostate (TURP) remains ever-popular in the United States and thus the market is enjoying normal growth in the country.

Technological Advancement Informing Growth of the Market in Canada

The CAGR for the benign prostatic hyperplasia (BPH) prostate treatment market in Canada is tipped to be 3.1% over the forecast period. Some of the key factors driving the growth are:

Canadian companies are increasingly taking the help of technology and making the newest treatment forms available to consumers. Thus, the market is in for growth in the country.
Irregular eating habits of a significant portion of Canadian consumers are leading to increased development of BPH patients in the country. Thus, BPH treatments are being sought in increasing measure in Canada.

Constant Innovation Through Research Affects Market Positively in the United Kingdom

The CAGR for the benign prostatic hyperplasia (BPH) prostate treatment market in the United Kingdom is tipped to be 3.7% over the forecast period. Some of the key factors driving the growth are:

Research regarding BPH is being encouraged in the United Kingdom and the market is benefitting as a result. For example, in November 2023, the transurethral water-jet ablation treatment was made available country-wide in the United Kingdom after limited trials of five years.
In January 2024, King Charles of the United Kingdom was affected by and underwent surgery for benign prostatic hyperplasia, raising the profile of BPH treatment in the country.

Governmental Concessions for BPH Treatment Sees the Market Enlarge in France

The market is expected to register a CAGR of 3.3% in France for the forecast period. Some of the key trends include:

France’s government has taken steps to lower the cost of BPH treatment, which is helping the market’s cause in the country. For example, in March 2021, the Urolift implant procedure, courtesy of Teleflex Incorporated, was made reimbursable to patients above 50 years of age in France.
Growing popularity of minimally invasive procedures in France sees BPH treatment of the minimally invasive nature progress in the country.

Development of New Supplements Freshening Up the Demand for BPH Treatment in Italy

The market is expected to register a CAGR of 3.5% in Italy over the forecast period. Some of the key trends include:

Designing new supplements is aiding the market’s cause in Italy. For example, in 2021, trials found a whole tomato based food supplement eased the pain of men afflicted with benign prostatic hyperplasia in Italy.
Rapidly aging population of Italy is developing prostate disorders at a greater rate and thus BPH treatment demand is increasing in the country.

Competitive Landscape in the Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market

The benign prostatic hyperplasia (BPH) prostate treatment market is competitive, though a few companies are prominent in the market. One of the well-established companies in the market is Pfizer Inc., who are concentrated on expansion through its alpha-blockers range.

Other players in the market are implementing strategies such as acquisitions and mergers to get a competitive edge. Research and development are also given importance by these market players.

Recent Developments in the Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market

In May 2023, the English football club Sutton United was sponsored by Ideal Medical Solutions Ltd. The sponsorship aimed to raise awareness of the Elesta Echo-Laser treatment device for BPH.
In February 2023, it was announced that the New Hall Hospital in Bodenham, England will receive equipment for the new ablation treatment procedure of BPH. The treatment uses imaging, robotics, and a heat-free water jet.
In June 2022, the first BPH treatment with the iTind device was done in Canada by Olympus.

Key Companies in the Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market

Pfizer Inc.
NxThera Inc.
NeoTract Inc.
Sanofi S.A
GlaxoSmithKline Plc.
Allergan Plc.
Teva Pharmaceutical Industries Ltd.
Mylan N.V.
Eli Lily & Company
Cardinal Health Inc.

Key Coverage in the Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market Industry Report

Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market Size and Share Analysis
Global BPH Treatment Device Market Forecast
BPH therapy market coverage
Prostate enlargement treatment market assessment
BPH medication market report
Emerging trends in surgical BPH treatment analysis

Key Segments

By Treatment Type:

BPH Drugs
- Alpha Blockers
- 5-Alpha Reductase Inhibitors
- Phosphodiesterase-5 (PDE-5) Inhibitors
- Muscarinic Receptor Antagonist (MRA)
- Combination Drug
BPH Devices
- Prostatic Stents
- Suture Base Implant Systems
- Transurethral RF Thermal Therapy Devices

By Distribution Channel:

Institutional Sales
- Hospitals
- Ambulatory Surgical Centres
- Specialty Clinics
Retail Sales
- Retail Pharmacies
- Drug Stores
Online Pharmacies

By Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East and Africa (MEA)

Frequently Asked Questions

How Big is the Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market?

The benign prostatic hyperplasia (BPH) prostate treatment market size is expected to be worth US$ 33,031.10 million in 2024.

How Big Will the Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market Be in 2034?

The benign prostatic hyperplasia (BPH) prostate treatment market is estimated to get as big as US$ 47,045.80 million in 2034.

How will the Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market Progress in the United States?

The CAGR of the benign prostatic hyperplasia (BPH) prostate treatment market during the 2024 to 2034 period in the United States is estimated to be 4.0%.

What are the Segments of the Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market?

The benign prostatic hyperplasia (BPH) prostate treatment market can be divided into the following segments: treatment type and distribution channel.

What is the Scope of the Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market?

The benign prostatic hyperplasia (BPH) prostate treatment market is expected to grow at a CAGR of 3.6% over the period from 2024 to 2034.

Who are the Key Players in the Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market Industry?

Pfizer Inc., NxThera Inc., NeoTract Inc., and Sanofi S.A. are some of the key companies in the benign prostatic hyperplasia (BPH) prostate treatment Market.

Table of Content

1. Executive Summary

1.1. Global Market Outlook

1.2. Demand-side Trends

1.3. Supply-side Trends

1.4. Technology Roadmap Analysis

1.5. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

3. Market Background

3.1. Market Dynamics

3.1.1. Drivers

3.1.2. Restraints

3.1.3. Opportunity

3.1.4. Trends

3.2. Scenario Forecast

3.2.1. Demand in Optimistic Scenario

3.2.2. Demand in Likely Scenario

3.2.3. Demand in Conservative Scenario

3.3. Opportunity Map Analysis

3.4. Investment Feasibility Matrix

3.5. PESTLE and Porter’s Analysis

3.6. Regulatory Landscape

3.6.1. By Key Regions

3.6.2. By Key Countries

3.7. Regional Parent Market Outlook

4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034

4.1. Historical Market Size Value (US$ Million) Analysis, 2019 to 2023

4.2. Current and Future Market Size Value (US$ Million) Projections, 2024 to 2034

4.2.1. Y-o-Y Growth Trend Analysis

4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Treatment Type

5.1. Introduction / Key Findings

5.2. Historical Market Size Value (US$ Million) Analysis By Treatment Type, 2019 to 2023

5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment Type, 2024 to 2034

5.3.1. BPH Drugs

5.3.1.1. Alpha Blockers

5.3.1.2. 5-Aplha Reductase Inhibitors

5.3.1.3. Phosphodiesterase-5 (PDE-5) Inhibitors

5.3.1.4. Muscarinic Receptor Antagonist (MRA)

5.3.1.5. Combination Drug

5.3.2. BPH Devices

5.3.2.1. Prostatic Stents

5.3.2.2. Suture Base Implant Systems

5.3.2.3. Transurethral RF Thermal Therapy Devices

5.4. Y-o-Y Growth Trend Analysis By Treatment Type, 2019 to 2023

5.5. Absolute $ Opportunity Analysis By Treatment Type, 2024 to 2034

6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel

6.1. Introduction / Key Findings

6.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2019 to 2023

6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2024 to 2034

6.3.1. Institutional Sales

6.3.1.1. Hospitals

6.3.1.2. Ambulatory Surgical Centres

6.3.1.3. Specialty Clinics

6.3.2. Retail Sales

6.3.2.1. Retail Pharmacies

6.3.2.2. Drug Stores

6.3.3. Online Pharmacies

6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2019 to 2023

6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2024 to 2034

7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region

7.1. Introduction

7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2019 to 2023

7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2024 to 2034

7.3.1. North America

7.3.2. Latin America

7.3.3. Western Europe

7.3.4. Eastern Europe

7.3.5. South Asia and Pacific

7.3.6. East Asia

7.3.7. Middle East and Africa

7.4. Market Attractiveness Analysis By Region

8. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023

8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034

8.2.1. By Country

8.2.1.1. USA

8.2.1.2. Canada

8.2.2. By Treatment Type

8.2.3. By Distribution Channel

8.3. Market Attractiveness Analysis

8.3.1. By Country

8.3.2. By Treatment Type

8.3.3. By Distribution Channel

8.4. Key Takeaways

9. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023

9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034

9.2.1. By Country

9.2.1.1. Brazil

9.2.1.2. Mexico

9.2.1.3. Rest of Latin America

9.2.2. By Treatment Type

9.2.3. By Distribution Channel

9.3. Market Attractiveness Analysis

9.3.1. By Country

9.3.2. By Treatment Type

9.3.3. By Distribution Channel

9.4. Key Takeaways

10. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023

10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034

10.2.1. By Country

10.2.1.1. Germany

10.2.1.2. UK

10.2.1.3. France

10.2.1.4. Spain

10.2.1.5. Italy

10.2.1.6. Rest of Western Europe

10.2.2. By Treatment Type

10.2.3. By Distribution Channel

10.3. Market Attractiveness Analysis

10.3.1. By Country

10.3.2. By Treatment Type

10.3.3. By Distribution Channel

10.4. Key Takeaways

11. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023

11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034

11.2.1. By Country

11.2.1.1. Poland

11.2.1.2. Russia

11.2.1.3. Czech Republic

11.2.1.4. Romania

11.2.1.5. Rest of Eastern Europe

11.2.2. By Treatment Type

11.2.3. By Distribution Channel

11.3. Market Attractiveness Analysis

11.3.1. By Country

11.3.2. By Treatment Type

11.3.3. By Distribution Channel

11.4. Key Takeaways

12. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023

12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034

12.2.1. By Country

12.2.1.1. India

12.2.1.2. Bangladesh

12.2.1.3. Australia

12.2.1.4. New Zealand

12.2.1.5. Rest of South Asia and Pacific

12.2.2. By Treatment Type

12.2.3. By Distribution Channel

12.3. Market Attractiveness Analysis

12.3.1. By Country

12.3.2. By Treatment Type

12.3.3. By Distribution Channel

12.4. Key Takeaways

13. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023

13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034

13.2.1. By Country

13.2.1.1. China

13.2.1.2. Japan

13.2.1.3. South Korea

13.2.2. By Treatment Type

13.2.3. By Distribution Channel

13.3. Market Attractiveness Analysis

13.3.1. By Country

13.3.2. By Treatment Type

13.3.3. By Distribution Channel

13.4. Key Takeaways

14. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023

14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034

14.2.1. By Country

14.2.1.1. GCC Countries

14.2.1.2. South Africa

14.2.1.3. Israel

14.2.1.4. Rest of MEA

14.2.2. By Treatment Type

14.2.3. By Distribution Channel

14.3. Market Attractiveness Analysis

14.3.1. By Country

14.3.2. By Treatment Type

14.3.3. By Distribution Channel

14.4. Key Takeaways

15. Key Countries Market Analysis

15.1. USA

15.1.1. Market Share Analysis, 2023

15.1.1.1. By Treatment Type

15.1.1.2. By Distribution Channel

15.2. Canada

15.2.1. Market Share Analysis, 2023

15.2.1.1. By Treatment Type

15.2.1.2. By Distribution Channel

15.3. Brazil

15.3.1. Market Share Analysis, 2023

15.3.1.1. By Treatment Type

15.3.1.2. By Distribution Channel

15.4. Mexico

15.4.1. Market Share Analysis, 2023

15.4.1.1. By Treatment Type

15.4.1.2. By Distribution Channel

15.5. Germany

15.5.1. Market Share Analysis, 2023

15.5.1.1. By Treatment Type

15.5.1.2. By Distribution Channel

15.6. UK

15.6.1. Market Share Analysis, 2023

15.6.1.1. By Treatment Type

15.6.1.2. By Distribution Channel

15.7. France

15.7.1. Market Share Analysis, 2023

15.7.1.1. By Treatment Type

15.7.1.2. By Distribution Channel

15.8. Spain

15.8.1. Market Share Analysis, 2023

15.8.1.1. By Treatment Type

15.8.1.2. By Distribution Channel

15.9. Italy

15.9.1. Market Share Analysis, 2023

15.9.1.1. By Treatment Type

15.9.1.2. By Distribution Channel

15.10. Poland

15.10.1. Market Share Analysis, 2023

15.10.1.1. By Treatment Type

15.10.1.2. By Distribution Channel

15.11. Russia

15.11.1. Market Share Analysis, 2023

15.11.1.1. By Treatment Type

15.11.1.2. By Distribution Channel

15.12. Czech Republic

15.12.1. Market Share Analysis, 2023

15.12.1.1. By Treatment Type

15.12.1.2. By Distribution Channel

15.13. Romania

15.13.1. Market Share Analysis, 2023

15.13.1.1. By Treatment Type

15.13.1.2. By Distribution Channel

15.14. India

15.14.1. Market Share Analysis, 2023

15.14.1.1. By Treatment Type

15.14.1.2. By Distribution Channel

15.15. Bangladesh

15.15.1. Market Share Analysis, 2023

15.15.1.1. By Treatment Type

15.15.1.2. By Distribution Channel

15.16. Australia

15.16.1. Market Share Analysis, 2023

15.16.1.1. By Treatment Type

15.16.1.2. By Distribution Channel

15.17. New Zealand

15.17.1. Market Share Analysis, 2023

15.17.1.1. By Treatment Type

15.17.1.2. By Distribution Channel

15.18. China

15.18.1. Market Share Analysis, 2023

15.18.1.1. By Treatment Type

15.18.1.2. By Distribution Channel

15.19. Japan

15.19.1. Market Share Analysis, 2023

15.19.1.1. By Treatment Type

15.19.1.2. By Distribution Channel

15.20. South Korea

15.20.1. Market Share Analysis, 2023

15.20.1.1. By Treatment Type

15.20.1.2. By Distribution Channel

15.21. GCC Countries

15.21.1. Market Share Analysis, 2023

15.21.1.1. By Treatment Type

15.21.1.2. By Distribution Channel

15.22. South Africa

15.22.1. Market Share Analysis, 2023

15.22.1.1. By Treatment Type

15.22.1.2. By Distribution Channel

15.23. Israel

15.23.1. Market Share Analysis, 2023

15.23.1.1. By Treatment Type

15.23.1.2. By Distribution Channel

16. Market Structure Analysis

16.1. Competition Dashboard

16.2. Competition Benchmarking

16.3. Market Share Analysis of Top Players

16.3.1. By Regional

16.3.2. By Treatment Type

16.3.3. By Distribution Channel

17. Competition Analysis

17.1. Competition Deep Dive

17.1.1. Pfizer Inc.

17.1.1.1. Overview

17.1.1.2. Product Portfolio

17.1.1.3. Profitability by Market Segments

17.1.1.4. Sales Footprint

17.1.1.5. Strategy Overview

17.1.1.5.1. Marketing Strategy

17.1.2. NxThera Inc.

17.1.2.1. Overview

17.1.2.2. Product Portfolio

17.1.2.3. Profitability by Market Segments

17.1.2.4. Sales Footprint

17.1.2.5. Strategy Overview

17.1.2.5.1. Marketing Strategy

17.1.3. NeoTract Inc.

17.1.3.1. Overview

17.1.3.2. Product Portfolio

17.1.3.3. Profitability by Market Segments

17.1.3.4. Sales Footprint

17.1.3.5. Strategy Overview

17.1.3.5.1. Marketing Strategy

17.1.4. Sanofi S.A

17.1.4.1. Overview

17.1.4.2. Product Portfolio

17.1.4.3. Profitability by Market Segments

17.1.4.4. Sales Footprint

17.1.4.5. Strategy Overview

17.1.4.5.1. Marketing Strategy

17.1.5. GlaxoSmithKline Plc.

17.1.5.1. Overview

17.1.5.2. Product Portfolio

17.1.5.3. Profitability by Market Segments

17.1.5.4. Sales Footprint

17.1.5.5. Strategy Overview

17.1.5.5.1. Marketing Strategy

17.1.6. Allergan Plc.

17.1.6.1. Overview

17.1.6.2. Product Portfolio

17.1.6.3. Profitability by Market Segments

17.1.6.4. Sales Footprint

17.1.6.5. Strategy Overview

17.1.6.5.1. Marketing Strategy

17.1.7. Teva Pharmaceutical Industries Ltd.

17.1.7.1. Overview

17.1.7.2. Product Portfolio

17.1.7.3. Profitability by Market Segments

17.1.7.4. Sales Footprint

17.1.7.5. Strategy Overview

17.1.7.5.1. Marketing Strategy

17.1.8. Mylan N.V.

17.1.8.1. Overview

17.1.8.2. Product Portfolio

17.1.8.3. Profitability by Market Segments

17.1.8.4. Sales Footprint

17.1.8.5. Strategy Overview

17.1.8.5.1. Marketing Strategy

17.1.9. Eli Lily & Company

17.1.9.1. Overview

17.1.9.2. Product Portfolio

17.1.9.3. Profitability by Market Segments

17.1.9.4. Sales Footprint

17.1.9.5. Strategy Overview

17.1.9.5.1. Marketing Strategy

17.1.10. Cardinal Health Inc.

17.1.10.1. Overview

17.1.10.2. Product Portfolio

17.1.10.3. Profitability by Market Segments

17.1.10.4. Sales Footprint

17.1.10.5. Strategy Overview

17.1.10.5.1. Marketing Strategy

18. Assumptions & Acronyms Used

19. Research Methodology

Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market

A Study of the Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market by Drugs and Devices